Tarcocimab

Phase 3Monoclonal antibody

KKodiak Sciences Inc

Tarcocimab is one of 72 small molecule programs targeting Diabetic Retinopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic RetinopathyActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Diabetic RetinopathyPhase 3

Active, not recruiting

Age-Related Macular DegenerationPhase 3

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

64 2

Eylea

Regeneron

Phase 3

44 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 9

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 10

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Age-Related Macular Degeneration

NCT06556368

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Active, not recruiting·KKodiak Sciences Inc·Phase 3·NCT06556368·675 enrolled

Diabetic Retinopathy1 trial

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Active, not recruiting·KKodiak Sciences Inc·Phase 3·NCT06270836·255 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tarcocimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tarcocimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tarcocimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kodiak Sciences Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: KKodiak Sciences Inc

Tarcocimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

Diabetic Retinopathy1 trial

References

Drug Info

Quick Facts

Related News